Boehringer's Dulcolax in agency review; Roche rolls back hep C drug prices in India;

> Boehringer Ingelheim's Dulcolax brand kicked off a global creative review, with pitches taking place at the end of June. Report

> Roche ($RHHBY) rolled back the prices on its Exxura treatment for hepatitis C in India, cutting the price by 65% for government institution purchasers. Report

> Bayer and Johnson & Johnson ($JNJ) have presentations on their anticoagulant drug Xarelto scheduled at the International Society on Thrombosis and Haemostasis meeting. Report

> Merck Serono won two prestigious Red Dot Awards for the design of its fertility drug-delivery pens. Release

> Rovi signed up to market Orvatez, a cholesterol-fighting drug that combines Merck & Co.'s ($MRK) Zetia (ezetimibe) with the statin drug atorvastatin, in Spain. Report

And Finally... The biosimilar naming debate is heating up as the FDA plans new guidance by the end of the year. Report

Suggested Articles

Eli Lilly bought full-page ads in more than a dozen newspapers in the U.S. to let people with diabetes who use Lilly drugs to know help is available.

Only months after a game-changing new approval for Vascepa, Amarin has lost a key fight over its patents—and now it's scrambling to respond.

Move over, Roche. There’s a new small cell lung cancer therapy on the scene, and it belongs to AstraZeneca.